Amneal Pharmaceuticals — Third Quarter 2026 Earnings Summary

Amneal Pharmaceuticals reported third-quarter 2026 net revenue of $863 million, representing a 10% increase from the prior year, driven by growth in its Affordable Medicines and Specialty segments. The company recorded a GAAP net loss of $22 million and a diluted loss per share of $0.06, while adjusted EBITDA rose 30% to $207 million and adjusted diluted earnings per share reached $0.26. Management updated its full-year 2026 guidance, raising net revenue expectations to a range of $3.15 billion to $3.25 billion and adjusted EBITDA to $800 million to $815 million. Key growth catalysts for the period included new product launches such as CREXONT, BREKIYA, and biosimilars, alongside the successful integration of the Kashiv acquisition.